speedometer Created with Sketch. Group 2 1839613 copy 2 Shape Group 4 1828885 Created with Sketch. Shape Created with Sketch. Continental Aktie ISIN DE000543900
Wertpapier hinzufügen für watchlist(s)
Jetzt anmelden
Wertpapier hinzufügen für portfolio(s)
Jetzt anmelden
Anmelden

Incyte Co.

WKN
WKN kopiert!
ISIN
ISIN kopiert!
Land USA
Symbol ICY
  1. Börse
  2. Aktien
  3. S&P 500 Index
  4. Incyte Co.
83,50€
+15,20€
+22,25%
Portfolio
Watchlist
BUYSELL
Broker
Geld
84,44
EUR
Brief
84,82
Tagestief
81,38
Tageshoch
90,50
52W-Tief
48,86
52W-Hoch
95,00
Aktuell gehandelt
872 Stück
Volumen
72.576 €
Marktkapitalisierung
17,287 Mrd. €
Eröffnung
90,50 €
Vortag
88,06 €
Dividende
0,00 €
Dividendenrendite
0,00%

Performance

1W
-2,07%
1M
-4,30%
3M
+19,10%
6M
+49,76%
1J
+24,41%
3J
+9,80%
5J
+28,46%
10J
-12,23%

NEWS

Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
16:10
www.zacks.com
Minuszeichen in New York: S&P 500 fällt zum Start des Montagshandels zurück
15:59
www.finanzen.net
Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer
15:30
www.benzinga.com
Boomi Named a 2025 Geo and Global AWS Partner Award Finalist
15:01
www.streetinsider.com
Incyte stock price target raised to $128 by Leerink on mCALR data
13:30
www.investing.com
Mizuho upgrades Incyte stock rating to Outperform on promising ASH data
11:54
www.investing.com
Mizuho stuft Incyte nach vielversprechenden ASH-Daten auf "Outperform" hoch
11:46
de.investing.com
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
02:02
www.prnewswire.com
Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs
01:35
markets.businessinsider.com
Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug
07. Dez.
www.investors.com
FDA fast-tracks Incyte drug for rare blood cancer
07. Dez.
seekingalpha.com
Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
07. Dez.
www.lelezard.com
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
07. Dez.
www.wallstreet-online.de
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
07. Dez.
www.prnewswire.com
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
06. Dez.
www.stocktitan.net
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
05. Dez.
www.prnewswire.com
DelveInsight Business Research, LLP: Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight
04. Dez.
www.finanznachrichten.de
Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight
04. Dez.
www.prnewswire.co.uk
Incyte Corp at Evercore ISI Healthcare Conference Transcript
04. Dez.
www.gurufocus.com
Pharmaceutical Market Transformation: AI Driving Innovation in a USD 3.03 Trillion Market by 2034
04. Dez.
www.biospace.com
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
04. Dez.
www.prnewswire.com
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03. Dez.
www.eagletribune.com
Myeloproliferative Disorder Treatment Market Size Report 2032 | Novartis AG, Incyte Corporation, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia, Shire, Pfizer, Takeda, Teva Pharmaceuticals, Merck
03. Dez.
www.openpr.com
Incyte taps Winnie Harlow to model vitiligo awareness, empowerment in new campaign
02. Dez.
www.fiercepharma.com
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
02. Dez.
investingnews.com
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
01. Dez.
www.gurufocus.com
China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
28. Nov.
www.prnewswire.com
DelveInsight Business Research LLP: Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight
27. Nov.
www.finanznachrichten.de
Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight
27. Nov.
www.prnewswire.co.uk
DataM Intelligence 4 Market Research LLP: Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
27. Nov.
www.finanznachrichten.de

INTERESSANT FÜR SIE

Biogen Idec
Biogen Idec+0,29%
Novonesis B
Novonesis B-1,22%
argenx SE
argenx SE+1,65%
Insmed
Insmed-1,14%
BeOne Medicines
BeOne Medicines-6,31%
Genmab ADR
Genmab ADR+0,73%
Royalty Pharma A
Royalty Pharma A-1,03%
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc-3,20%
Lonza Group
Lonza Group+1,07%
Amgen
Amgen-1,80%
Innovent Biologics
Innovent Biologics-4,95%
BeOne Medicines ADR
BeOne Medicines ADR+0,72%
Genmab
Genmab+0,66%
IDEXX Laboratories
IDEXX Laboratories-0,39%

Community Sentiment

News

16:10
15:59
15:30
15:01
13:30
11:54
11:46
02:02
01:35
07. Dez.
07. Dez.
07. Dez.
07. Dez.
07. Dez.
06. Dez.
05. Dez.
04. Dez.
04. Dez.
04. Dez.
04. Dez.
04. Dez.
03. Dez.
03. Dez.
02. Dez.
02. Dez.
01. Dez.
28. Nov.
27. Nov.
27. Nov.
27. Nov.

Gewinn und Verlustrechnung (GuV)

Profitabilität
EBIT-Marge
4,48%
Management-Effektivität
Gesamtkapitalrendite
0,64%
Eigenkapitalrendite
0,95%
Gewinn & Verlust
Umsatz
4,2 Mrd.
Anzahl Aktien
219,9 Mio.
Umsatz pro Mitarbeiter
1.404.771 EUR
Betriebsergebnis (EBIT)
164,9 Mio.
Ergebnis nach Steuern
32,6 Mio.

Bewertungskennzahlen

20212022202320242025e2026e2027e
KGV17,1952,8423,69460,5415,4414,3212,73
PEG-0,270,71-0,250,121,971,141,10
KCV21,7518,5528,5743,3611,9210,219,42
KBV4,304,092,713,88---

Dividende & Dividendenrendite

Umsatz & Gewinn (EBIT)

Anteilseigner

Kontakt

Incyte Corp. 1801 Augustine Cut-Off 19803 Wilmington USA
http://www.incyte.com
media@incyte.com
Telefon: +1-302-498-6700
Fax: +

Stammdaten

WKN
896133
Symbol
ICY
Branche
Biotechnologie
ISIN
US45337C1027
Land
USA
Sektor
Chemie

Porträt

Incyte Corp. ist ein Unternehmen mit Sitz in Wilmington, USA, das primär im Bereich Biopharmazeutische Produkte tätig ist. Die Sektorklassifizierung des Unternehmens basiert auf dem FactSet eigenen RBICS Sektorsystem.

Vorstand

Julian Baker (Chairman of Board of Directors)
Dr. Edmund Harrigan
Dr. Jacqualyn Fouse
Dr. Katherine High
Dr. Otis Brawley
Dr. Susanne Antonie Schaffert
Herve Hoppenot
Jean-Jacques Bienaimé
Paul Clancy
Hervé Hoppenot (Vorstandsvorsitzender)
Dr. Barry P. Flannelly
Dr. Steven H. Stein
Christiana Stamoulis
Denise Brashear
Jonathan E. Dickinson
Lee Heeson
Matteo Trotta
Michael Morrissey
Mohamed Issa
Pablo J. Cagnoni
Paula J. Swain
Sheila A. Denton
Vijay Iyengar